APPOLOGIES - THIS PAGE HAS NOT BEEN UPDATED, WE HOPE TO HAVE ALL NEW MATERIALS POSTED SOON
ADNP PUBLICATIONS
Below are links to medical and research publications regarding ADNP Syndrome / Helsmoortel - Van Der Aa Syndrome and activity dependent neuro-protective protein.
PUBLICATIONS WITH CONTRIBUTION INVOLVING ADNP KIDS RESEARCH FOUNDATION:
Sensory Reactivity Symptoms Are a Core Feature of ADNP Syndrome Irrespective of Autism Diagnosis
Siper PM, Layton C, Levy T, Lurie S, Benrey N, Zweifach J, Rowe M, Tang L, Guillory S, Halpern D, Giserman-Kiss I, Del Pilar Trelles M, Foss-Feig JH, De Rubeis S, Tavassoli T, Buxbaum JD, Kolevzon A.Genes (Basel). 2021 Feb 27;12(3):351. doi: 10.3390/genes12030351.PMID: 33673501
Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism
F. Kyle Satterstrom, Jack A. Kosmicki, Jiebiao Wang, ..., Kathryn Roeder, Mark J. Daly, Joseph D. Buxbaum
Cell 2020 Jan
Episignatures Stratifying Helsmoortel-Van Der Aa Syndrome Show Modest Correlation with Phenotype.
Breen MS, Garg P, Tang L, Mendonca D, Levy T, Barbosa M, Arnett AB, Kurtz-Nelson E, Agolini E, Battaglia A, Chiocchetti AG, Freitag CM, Garcia-Alcon A, Grammatico P, Hertz-Picciotto I, Ludena-Rodriguez Y, Moreno C, Novelli A, Parellada M, Pascolini G, Tassone F, Grice DE, Di Marino D, Bernier RA, Kolevzon A, Sharp AJ, Buxbaum JD, Siper PM, De Rubeis S.Am J Hum Genet. 2020 Sep 3;107(3):555-563. doi: 10.1016/j.ajhg.2020.07.003. Epub 2020 Aug 5.PMID: 32758449
The autism spectrum phenotype in ADNP syndrome.
Arnett AB, Rhoads CL, Hoekzema K, Turner TN, Gerdts J, Wallace AS, Bedrosian-Sermone S, Eichler EE, Bernier RA.
Autism Res. 2018 Sep;11(9):1300-1310. doi: 10.1002/aur.1980. Epub 2018 Aug 14.
Premature primary tooth eruption in cognitive/motor-delayed ADNP-mutated children.
Gozes I, Van Dijck A, Hacohen-Kleiman G, Grigg I, Karmon G, Giladi E, Eger M, Gabet Y, Pasmanik-Chor M, Cappuyns E, Elpeleg O, Kooy RF, Bedrosian-Sermone S.
Transl Psychiatry. 2017 Jul 4;7(7):e1166. doi: 10.1038/tp.2017.128.
www.mdpi.com/2073-4425/12/3/351/pdf
Clinical Presentation of a Complex Neurodevelopmental Disorder Caused by Mutations in ADNP.
Van Dijck A, Vulto-van Silfhout AT, Cappuyns E, van der Werf IM, Mancini GM, Tzschach A, Bernier R, Gozes I, Eichler EE, Romano C, Lindstrand A, Nordgren A; ADNP Consortium, Kvarnung M, Kleefstra T, de Vries BBA, Küry S, Rosenfeld JA, Meuwissen ME, Vandeweyer G, Kooy RF.
Biol Psychiatry. 2019 Feb 15;85(4):287-297. doi: 10.1016/j.biopsych.2018.02.1173. Epub 2018 Mar 15.
ADNP Consortium includes Bedrosian-Sermone S.
The Eight and a Half Year Journey of Undiagnosed AD: Gene Sequencing and Funding of Advanced Genetic Testing Has Led to Hope and New Beginnings.
Gozes I, Patterson MC, Van Dijck A, Kooy RF, Peeden JN, Eichenberger JA, Zawacki-Downing A, Bedrosian-Sermone S.
Front Endocrinol (Lausanne). 2017 May 19;8:107. doi: 10.3389/fendo.2017.00107. eCollection 2017.
The Compassionate Side of Neuroscience: Tony Sermone's Undiagnosed Genetic Journey--ADNPMutation.
Gozes I, Helsmoortel C, Vandeweyer G, Van der Aa N, Kooy F, Bedrosian-Sermone S.
J Mol Neurosci. 2015 Aug;56(4):751-757. doi: 10.1007/s12031-015-0586-6.
LIST OF ADDITONAL RELATED ADNP PUBLICATIONS:
Frank Kooy
Chromatin remodeler Activity-Dependent Neuroprotective Protein (ADNP) contributes to syndromic autism.
Claudio Peter D'Incal, Kirsten Esther Van Rossem, Kevin De Man, Anthony Konings, Anke Van Dijck, Ludovico Rizzuti, Alessandro Vitriolo, Giuseppe Testa, Illana Gozes, Wim Vanden Berghe,
2023 March 21, doi: 10.1186/s13148-023-01450-8
Single Cell ADNP Predictive of Human Muscle Disorders: Mouse Knockdown Results in Muscle Wasting.
Kapitansky O, Karmon G, Sragovich S, Hadar A, Shahoha M, Jaljuli I, Bikovski L, Giladi E, Palovics R, Iram T, Gozes I.Cells. 2020 Oct 19;9(10):2320. doi: 10.3390/cells9102320.PMID: 33086621
The ADNP Syndrome and CP201 (NAP) Potential and Hope.
Gozes I.Front Neurol. 2020 Nov 24;11:608444. doi: 10.3389/fneur.2020.608444. eCollection 2020.PMID: 33329371
Activity-dependent neuroprotective protein (ADNP)-end-binding protein (EB) interactions regulate microtubule dynamics toward protection against tauopathy.
Ivashko-Pachima Y, Gozes I.Prog Mol Biol Transl Sci. 2021;177:65-90. doi: 10.1016/bs.pmbts.2020.07.008. Epub 2020 Aug 14.PMID: 33453943
Sex-and Region-Dependent Expression of the Autism-Linked ADNP Correlates with Social- and Speech-Related Genes in the Canary Brain.
Hacohen-Kleiman G, Moaraf S, Kapitansky O, Gozes I.J Mol Neurosci. 2020 Nov;70(11):1671-1683. doi: 10.1007/s12031-020-01700-x. Epub 2020 Sep 14.PMID: 32926339
Developmental Predictors of Cognitive and Adaptive Outcomes in Genetic Subtypes of Autism Spectrum Disorder.
Arnett AB, Beighley JS, Kurtz-Nelson EC, Hoekzema K, Wang T, Bernier RA, Eichler EE.Autism Res. 2020 Oct;13(10):1659-1669. doi: 10.1002/aur.2385. Epub 2020 Sep 12.PMID: 32918531
ADNP Controls Gene Expression Through Local Chromatin Architecture by Association With BRG1 and CHD4.
Sun X, Yu W, Li L, Sun Y.Front Cell Dev Biol. 2020 Jul 1;8:553. doi: 10.3389/fcell.2020.00553. eCollection 2020.PMID: 32714933
Tauopathy in the young autistic brain: novel biomarker and therapeutic target.
Grigg I, Ivashko-Pachima Y, Hait TA, Korenková V, Touloumi O, Lagoudaki R, Van Dijck A, Marusic Z, Anicic M, Vukovic J, Kooy RF, Grigoriadis N, Gozes I.
ADNP promotes neural differentiation by modulating Wnt/beta-catenin signaling.Sun X, Peng X, Cao Y, Zhou Y, Sun Y., Nat Commun. 2020 Jun 12;11(1):2984. doi: 10.1038/s41467-020-16799-0.PMID: 32533114
Early behavioral and developmental interventions in ADNP-syndrome: A case report of SWI/SNF-related neurodevelopmental syndrome.
Shillington A, Pedapati E, Hopkin R, Suhrie K.Mol Genet Genomic Med. 2020 Jun;8(6):e1230. doi: 10.1002/mgg3.1230. Epub 2020 Apr 10.PMID: 32275126
Microbiota changes associated with ADNP deficiencies: rapid indicators for NAP (CP201) treatment of the ADNP syndrome and beyond.
Kapitansky O, Giladi E, Jaljuli I, Bereswill S, Heimesaat MM, Gozes I.J Neural Transm (Vienna). 2020 Feb;127(2):251-263. doi: 10.1007/s00702-020-02155-5. Epub 2020 Feb 18.PMID: 32072336
VIP/PACAP-Based Drug Development: The ADNP/NAP-Derived Mirror Peptides SKIP and D-SKIP Exhibit Distinctive in vivo and in silico Effects.
Sragovich S, Amram N, Yeheskel A, Gozes I.Front Cell Neurosci. 2020 Jan 14;13:589. doi: 10.3389/fncel.2019.00589. eCollection 2019.PMID: 31992971
The autism-mutated ADNP plays a key role in stress response.
Sragovich S, Ziv Y, Vaisvaser S, Shomron N, Hendler T, Gozes I.Transl Psychiatry. 2019 Sep 18;9(1):235. doi: 10.1038/s41398-019-0569-4.PMID: 31534115
The ChAHP Complex Counteracts Chromatin Looping at CTCF Sites that Emerged from SINE Expansions in Mouse.
Kaaij LJT, Mohn F, van der Weide RH, de Wit E, Bühler M.Cell. 2019 Sep 5;178(6):1437-1451.e14. doi: 10.1016/j.cell.2019.08.007.PMID: 31491387
NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies.
Ivashko-Pachima Y, Maor-Nof M, Gozes I.
PLoS One. 2019 Mar 13;14(3):e0213666. doi: 10.1371/journal.pone.0213666. eCollection 2019.
Cellular and animal models of skin alterations in the autism-related ADNP syndrome.
Mollinedo P, Kapitansky O, Gonzalez-Lamuño D, Zaslavsky A, Real P, Gozes I, Gandarillas A, Fernandez-Luna JL.
Sci Rep. 2019 Jan 24;9(1):736. doi: 10.1038/s41598-018-36859-2.
The autism/neuroprotection-linked ADNP/NAP regulate the excitatory glutamatergic synapse.
Sragovich S, Malishkevich A, Piontkewitz Y, Giladi E, Touloumi O, Lagoudaki R, Grigoriadis N, GozesI.
Transl Psychiatry. 2019 Jan 15;9(1):2. doi: 10.1038/s41398-018-0357-6.
Atypical Auditory Brainstem Response and Protein Expression Aberrations Related to ASD and Hearing Loss in the Adnp Haploinsufficient Mouse Brain.
Hacohen-Kleiman G, Yizhar-Barnea O, Touloumi O, Lagoudaki R, Avraham KB, Grigoriadis N, GozesI.
Neurochem Res. 2019 Jan 18. doi: 10.1007/s11064-019-02723-6. [Epub ahead of print]
ADNP Regulates Cognition: A Multitasking Protein.
Gozes I.
Front Neurosci. 2018 Nov 26;12:873. doi: 10.3389/fnins.2018.00873. eCollection 2018. No abstract available.
NAP Protects against Tau Hyperphosphorylation Through GSK3.
Ivashko-Pachima Y, Gozes I.
Curr Pharm Des. 2018;24(33):3868-3877. doi: 10.2174/1381612824666181112105954.
Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome.
Hacohen-Kleiman G, Sragovich S, Karmon G, Gao AYL, Grigg I, Pasmanik-Chor M, Le A, Korenková V, McKinney RA, Gozes I.
J Clin Invest. 2018 Nov 1;128(11):4956-4969. doi: 10.1172/JCI98199. Epub 2018 Sep 24.
Activity-dependent neuroprotective protein (ADNP) is an alcohol-responsive gene and negative regulator of alcohol consumption in female mice.
Ziv Y, Rahamim N, Lezmy N, Even-Chen O, Shaham O, Malishkevich A, Giladi E, Elkon R, Gozes I, Barak S.
Neuropsychopharmacology. 2019 Jan;44(2):415-424. doi: 10.1038/s41386-018-0132-7. Epub 2018 Jun 27.
Mutations in ADNP affect expression and subcellular localization of the protein.
Cappuyns E, Huyghebaert J, Vandeweyer G, Kooy RF.
Cell Cycle. 2018;17(9):1068-1075. doi: 10.1080/15384101.2018.1471313. Epub 2018 Jul 17.
The autism spectrum phenotype in ADNP syndrome.
Arnett AB, Rhoads CL, Hoekzema K, Turner TN, Gerdts J, Wallace AS, Bedrosian-Sermone S, Eichler EE, Bernier RA.
Autism Res. 2018 Sep;11(9):1300-1310. doi: 10.1002/aur.1980. Epub 2018 Aug 14.
Clinical Presentation of a Complex Neurodevelopmental Disorder Caused by Mutations in ADNP.
Van Dijck A, Vulto-van Silfhout AT, Cappuyns E, van der Werf IM, Mancini GM, Tzschach A, Bernier R, Gozes I, Eichler EE, Romano C, Lindstrand A, Nordgren A; ADNP Consortium, Kvarnung M, Kleefstra T, de Vries BBA, Küry S, Rosenfeld JA, Meuwissen ME, Vandeweyer G, Kooy RF.
Biol Psychiatry. 2019 Feb 15;85(4):287-297. doi: 10.1016/j.biopsych.2018.02.1173. Epub 2018 Mar 15.
A heterozygous microdeletion of 20q13.13 encompassing ADNP gene in a child with Helsmoortel-van der Aa syndrome.
Huynh MT, Boudry-Labis E, Massard A, Thuillier C, Delobel B, Duban-Bedu B, Vincent-Delorme C.
Eur J Hum Genet. 2018 Oct;26(10):1497-1501. doi: 10.1038/s41431-018-0165-8. Epub 2018 Jun 13.
Activity-dependent neuroprotective protein recruits HP1 and CHD4 to control lineage-specifying genes.
Ostapcuk V, Mohn F, Carl SH, Basters A, Hess D, Iesmantavicius V, Lampersberger L, Flemr M, Pandey A, Thomä NH, Betschinger J, Bühler M.
Nature. 2018 May;557(7707):739-743. doi: 10.1038/s41586-018-0153-8. Epub 2018 May 23.
Anti-inflammatory Effects of the Octapeptide NAP in Human Microbiota-Associated Mice Suffering from Subacute Ileitis.
Escher U, Giladi E, Dunay IR, Bereswill S, Gozes I, Heimesaat MM.
Eur J Microbiol Immunol (Bp). 2018 May 23;8(2):34-40. doi: 10.1556/1886.2018.00006. eCollection 2018 Jun 25.
ADNP, a Microtubule Interacting Protein, Provides Neuroprotection Through End Binding Proteins and Tau: An Amplifier Effect.
Gozes I, Ivashko-Pachima Y, Sayas CL.
Front Mol Neurosci. 2018 May 1;11:151. doi: 10.3389/fnmol.2018.00151. eCollection 2018. No abstract available.
Longitudinal ophthalmic findings in a child with Helsmoortel-Van der Aa Syndrome.
Gale MJ, Titus HE, Harman GA, Alabduljalil T, Dennis A, Wilson JL, Koeller DM, Finanger E, Blasco PA, Chiang PW, Karr DJ, Yang P.
Am J Ophthalmol Case Rep. 2018 Mar 13;10:244-248. doi: 10.1016/j.ajoc.2018.03.015. eCollection 2018 Jun.
Helsmoortel-Van der Aa Syndrome as emerging clinical diagnosis in intellectually disabled children with autistic traits and ocular involvement.
Pascolini G, Agolini E, Majore S, Novelli A, Grammatico P, Digilio MC.
Eur J Paediatr Neurol. 2018 May;22(3):552-557. doi: 10.1016/j.ejpn.2018.01.024. Epub 2018 Feb 3.
The octapetide NAP alleviates intestinal and extra-intestinal anti-inflammatory sequelae of acute experimental colitis.
Heimesaat MM, Giladi E, Kühl AA, Bereswill S, Gozes I.
Peptides. 2018 Mar;101:1-9. doi: 10.1016/j.peptides.2017.12.023. Epub 2017 Dec 27.
Specific protein biomarker patterns for Alzheimer's disease: improved diagnostics in progress.
Gozes I.
EPMA J. 2017 Sep 4;8(3):255-259. doi: 10.1007/s13167-017-0110-x. eCollection 2017 Sep. Review.
ADNP Plays a Key Role in Autophagy: From Autism to Schizophrenia and Alzheimer's Disease.
Sragovich S, Merenlender-Wagner A, Gozes I.
Bioessays. 2017 Nov;39(11). doi: 10.1002/bies.201700054. Epub 2017 Sep 21. Review.
Premature primary tooth eruption in cognitive/motor-delayed ADNP-mutated children.
Gozes I, Van Dijck A, Hacohen-Kleiman G, Grigg I, Karmon G, Giladi E, Eger M, Gabet Y, Pasmanik-Chor M, Cappuyns E, Elpeleg O, Kooy RF, Bedrosian-Sermone S.
Transl Psychiatry. 2017 Jul 4;7(7):e1166. doi: 10.1038/tp.2017.128.
The Eight and a Half Year Journey of Undiagnosed AD: Gene Sequencing and Funding of Advanced Genetic Testing Has Led to Hope and New Beginnings.
Gozes I, Patterson MC, Van Dijck A, Kooy RF, Peeden JN, Eichenberger JA, Zawacki-Downing A, Bedrosian-Sermone S.
Front Endocrinol (Lausanne). 2017 May 19;8:107. doi: 10.3389/fendo.2017.00107. eCollection 2017.
ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy.
Ivashko-Pachima Y, Sayas CL, Malishkevich A, Gozes I.
Mol Psychiatry. 2017 Sep;22(9):1335-1344. doi: 10.1038/mp.2016.255. Epub 2017 Jan 24.
Prenatal diagnosis of complex phenotype in a 13-week-old fetus with an interstitial multigene deletion 20q13.13.-q13.2 by chromosomal microarray.
Stipoljev F, Miric-Tesanic D, Hafner T, Barbalic M, Logara M, Lasan-Trcic R, Vicic A, Gjergja-Juraski R.
Eur J Med Genet. 2017 Nov;60(11):589-594. doi: 10.1016/j.ejmg.2017.08.010. Epub 2017 Aug 12.
Novel features of Helsmoortel-Van der Aa/ADNP syndrome in a boy with a known pathogenic mutation in the ADNP gene detected by exome sequencing.
Li C, Wang Y, Szybowska M.
Am J Med Genet A. 2017 May 5. doi: 10.1002/ajmg.a.38201. [Epub ahead of print] No abstract available.
Further evidence that a blepharophimosis syndrome phenotype is associated with a specific class of mutation in the ADNP gene.
Takenouchi T, Miwa T, Sakamoto Y, Sakaguchi Y, Uehara T, Takahashi T, Kosaki K.
Am J Med Genet A. 2017 Jun;173(6):1631-1634. doi: 10.1002/ajmg.a.38126.
Sexual divergence in activity-dependent neuroprotective protein impacting autism, schizophrenia, and Alzheimer's disease.
Gozes I.
J Neurosci Res. 2017 Jan 2;95(1-2):652-660. doi: 10.1002/jnr.23808. Review.
D-SAL and NAP: Two Peptides Sharing a SIP Domain.
Gozes I, Sragovich S, Schirer Y, Idan-Feldman A.
J Mol Neurosci. 2016 Jun;59(2):220-31. doi: 10.1007/s12031-015-0701-8.
Sexual divergence in microtubule function: the novel intranasal microtubule targeting SKIP normalizes axonal transport and enhances memory.
Amram N, Hacohen-Kleiman G, Sragovich S, Malishkevich A, Katz J, Touloumi O, Lagoudaki R, Grigoriadis NC, Giladi E, Yeheskel A, Pasmanik-Chor M, Jouroukhin Y, Gozes I.
Mol Psychiatry. 2016 Oct;21(10):1467-76. doi: 10.1038/mp.2015.208. Epub 2016 Jan 19.
Additional data on the clinical phenotype of Helsmoortel-Van der Aa syndrome associated with a novel truncating mutation in ADNP gene.
Krajewska-Walasek M, Jurkiewicz D, Piekutowska-Abramczuk D, Kucharczyk M, Chrzanowska KH, Jezela-Stanek A, Ciara E.
Am J Med Genet A. 2016 Jun;170(6):1647-50. doi: 10.1002/ajmg.a.37641.
Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers.
Malishkevich A, Marshall GA, Schultz AP, Sperling RA, Aharon-Peretz J, Gozes I.
J Alzheimers Dis. 2016;50(1):249-60. doi: 10.3233/JAD-150799.
ADNP: in search for molecular mechanisms and innovative therapeutic strategies for frontotemporal degeneration.
Gozes I, Ivashko-Pachima Y.
Front Aging Neurosci. 2015 Oct 29;7:205. doi: 10.3389/fnagi.2015.00205. eCollection 2015. Review.
Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model.
Vaisburd S, Shemer Z, Yeheskel A, Giladi E, Gozes I.
Sci Rep. 2015 Nov 10;5:16300. doi: 10.1038/srep16300.
Anti-Inflammatory Properties of NAP in Acute Toxoplasma Gondii-Induced Ileitis in Mice.
Heimesaat MM, Fischer A, Kühl AA, Göbel UB, Gozes I, Bereswill S.
Eur J Microbiol Immunol (Bp). 2015 Sep 18;5(3):210-20. doi: 10.1556/1886.2015.00025. eCollection 2015 Sep.
ADNP/ADNP2 expression in oligodendrocytes: implication for myelin-related neurodevelopment.
Malishkevich A, Leyk J, Goldbaum O, Richter-Landsberg C, Gozes I.
J Mol Neurosci. 2015 Oct;57(2):304-13. doi: 10.1007/s12031-015-0640-4.
The Compassionate Side of Neuroscience: Tony Sermone's Undiagnosed Genetic Journey--ADNPMutation.
Gozes I, Helsmoortel C, Vandeweyer G, Van der Aa N, Kooy F, Sermone SB.
J Mol Neurosci. 2015 Aug;56(4):751-757. doi: 10.1007/s12031-015-0586-6.
The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP.
Gozes I.
Biol Chem. 2016 Mar;397(3):177-84. doi: 10.1515/hsz-2015-0152. Review.
ADNP-Related Intellectual Disability and Autism Spectrum Disorder.
Van Dijck A, Helsmoortel C, Vandeweyer G, Kooy F.
In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews®[Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2016 Apr 7.
ADNP: A major autism mutated gene is differentially distributed (age and gender) in the songbird brain.
Hacohen Kleiman G, Barnea A, Gozes I.
Peptides. 2015 Oct;72:75-9. doi: 10.1016/j.peptides.2015.04.008. Epub 2015 Apr 17.
Activity-dependent neuroprotective protein (ADNP) exhibits striking sexual dichotomy impacting on autistic and Alzheimer's pathologies.
Malishkevich A, Amram N, Hacohen-Kleiman G, Magen I, Giladi E, Gozes I.
Transl Psychiatry. 2015 Feb 3;5:e501. doi: 10.1038/tp.2014.138.
Activity-dependent neuroprotective protein (ADNP): from autism to Alzheimer's disease.
Gozes I.
Springerplus. 2015 Jun 12;4(Suppl 1):L37. doi: 10.1186/2193-1801-4-S1-L37. eCollection 2015. No abstract available.
New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia.
Merenlender-Wagner A, Shemer Z, Touloumi O, Lagoudaki R, Giladi E, Andrieux A, Grigoriadis NC, Gozes I.
Autophagy. 2014;10(12):2324-32. doi: 10.4161/15548627.2014.984274.
Activity-dependent neuroprotective protein (ADNP): a case study for highly conserved chordata-specific genes shaping the brain and mutated in cancer.
Gozes I, Yeheskel A, Pasmanik-Chor M.
J Alzheimers Dis. 2015;45(1):57-73. doi: 10.3233/JAD-142490.
The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins.
Oz S, Kapitansky O, Ivashco-Pachima Y, Malishkevich A, Giladi E, Skalka N, Rosin-Arbesfeld R, Mittelman L, Segev O, Hirsch JA, Gozes I.
Mol Psychiatry. 2014 Oct;19(10):1115-24. doi: 10.1038/mp.2014.97. Epub 2014 Sep 2.
The transcriptional regulator ADNP links the BAF (SWI/SNF) complexes with autism.
Vandeweyer G, Helsmoortel C, Van Dijck A, Vulto-van Silfhout AT, Coe BP, Bernier R, Gerdts J, Rooms L, van den Ende J, Bakshi M, Wilson M, Nordgren A, Hendon LG, Abdulrahman OA, Romano C, de Vries BB, Kleefstra T, Eichler EE, Van der Aa N, Kooy RF.
Am J Med Genet C Semin Med Genet. 2014 Sep;166C(3):315-26. doi: 10.1002/ajmg.c.31413. Epub 2014 Aug 28.
Expansion of the clinical phenotype associated with mutations in activity-dependent neuroprotective protein.
Pescosolido MF, Schwede M, Johnson Harrison A, Schmidt M, Gamsiz ED, Chen WS, Donahue JP, Shur N, Jerskey BA, Phornphutkul C, Morrow EM.
J Med Genet. 2014 Sep;51(9):587-9. doi: 10.1136/jmedgenet-2014-102444. Epub 2014 Jul 23. No .
A SWI/SNF-related autism syndrome caused by de novo mutations in ADNP.
Helsmoortel C, Vulto-van Silfhout AT, Coe BP, Vandeweyer G, Rooms L, van den Ende J, Schuurs-Hoeijmakers JH, Marcelis CL, Willemsen MH, Vissers LE, Yntema HG, Bakshi M, Wilson M, Witherspoon KT, Malmgren H, Nordgren A, Annerén G, Fichera M, Bosco P, Romano C, de Vries BB, Kleefstra T, Kooy RF, Eichler EE, Van der Aa N.
Nat Genet. 2014 Apr;46(4):380-4. doi: 10.1038/ng.2899. Epub 2014 Feb 16.
Davunetide: Peptide therapeutic in neurological disorders.
Magen I, Gozes I.
Curr Med Chem. 2014;21(23):2591-8. Review.
Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide).
Gozes I, Iram T, Maryanovsky E, Arviv C, Rozenberg L, Schirer Y, Giladi E, Furman-Assaf S.
J Alzheimers Dis. 2014;40 Suppl 1:S23-36. doi: 10.3233/JAD-131664.
Novel marker for the onset of frontotemporal dementia: early increase in activity-dependent neuroprotective protein (ADNP) in the face of Tau mutation.
Schirer Y, Malishkevich A, Ophir Y, Lewis J, Giladi E, Gozes I.
PLoS One. 2014 Jan 29;9(1):e87383. doi: 10.1371/journal.pone.0087383. eCollection 2014.
NAP alpha-aminoisobutyric acid (IsoNAP).
Gozes I, Schirer Y, Idan-Feldman A, David M, Furman-Assaf S.
J Mol Neurosci. 2014 Jan;52(1):1-9. doi: 10.1007/s12031-013-0103-8.
Autophagy has a key role in the pathophysiology of schizophrenia.
Merenlender-Wagner A, Malishkevich A, Shemer Z, Udawela M, Gibbons A, Scarr E, Dean B, Levine J, Agam G, Gozes I.
Mol Psychiatry. 2015 Feb;20(1):126-32. doi: 10.1038/mp.2013.174. Epub 2013 Dec 24.
Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP).
Magen I, Gozes I.
Neuropeptides. 2013 Dec;47(6):489-95. doi: 10.1016/j.npep.2013.10.011. Epub 2013 Oct 24. Review.
The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities.
Oz S, Ivashko-Pachima Y, Gozes I.
PLoS One. 2012;7(12):e51458. doi: 10.1371/journal.pone.0051458. Epub 2012 Dec 14.
Neuropeptide GPCRs in neuroendocrinology: the case of activity-dependent neuroprotective protein (ADNP).
Gozes I.
Front Endocrinol (Lausanne). 2012 Nov 16;3:134. doi: 10.3389/fendo.2012.00134. eCollection 2012. No abstract available.
Novel evolutionary-conserved role for the activity-dependent neuroprotective protein (ADNP) family that is important for erythropoiesis.
Dresner E, Malishkevich A, Arviv C, Leibman Barak S, Alon S, Ofir R, Gothilf Y, Gozes I.
J Biol Chem. 2012 Nov 23;287(48):40173-85. doi: 10.1074/jbc.M112.387027. Epub 2012 Oct 15.
D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy.
Jouroukhin Y, Ostritsky R, Gozes I.
J Mol Neurosci. 2012 Nov;48(3):597-602. Review.
Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).
Gozes I.
Curr Pharm Des. 2011;17(31):3413-7. Review.
Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.
Shiryaev N, Pikman R, Giladi E, Gozes I.
Curr Pharm Des. 2011;17(25):2603-12. Review.
NAP (davunetide) provides functional and structural neuroprotection.
Gozes I.
Curr Pharm Des. 2011;17(10):1040-4. Review.
Ameliorative effect of NAP on laser-induced retinal damage.
Belokopytov M, Shulman S, Dubinsky G, Gozes I, Belkin M, Rosner M.
Acta Ophthalmol. 2011 Mar;89(2):e126-31. doi: 10.1111/j.1755-3768.2010.02041.x. Epub 2011 Feb 2.
Neuroprotective effects of NAP against excitotoxic brain damage in the newborn mice: implications for cerebral palsy.
Sokolowska P, Passemard S, Mok A, Schwendimann L, Gozes I, Gressens P.
Neuroscience. 2011 Jan 26;173:156-68. doi: 10.1016/j.neuroscience.2010.10.074. Epub 2010 Nov 10.
Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate.
Gozes I.
Peptides. 2011 Feb;32(2):428-31. doi: 10.1016/j.peptides.2010.10.030. Epub 2010 Nov 2. Review.
Tau pathology and future therapeutics.
Gozes I.
Curr Alzheimer Res. 2010 Dec;7(8):685-96. Review.
Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia.
Dresner E, Agam G, Gozes I.
Eur Neuropsychopharmacol. 2011 May;21(5):355-61. doi: 10.1016/j.euroneuro.2010.06.004. Epub 2010 Jul 3.
NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia.
Merenlender-Wagner A, Pikman R, Giladi E, Andrieux A, Gozes I.
Peptides. 2010 Jul;31(7):1368-73. doi: 10.1016/j.peptides.2010.04.011. Epub 2010 Apr 22.
Addressing Alzheimer's disease tangles: from NAP to AL-108.
Gozes I, Stewart A, Morimoto B, Fox A, Sutherland K, Schmeche D.
Curr Alzheimer Res. 2009 Oct;6(5):455-60. Review.
Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease.
Fernandez-Montesinos R, Torres M, Baglietto-Vargas D, Gutierrez A, Gozes I, Vitorica J, Pozo D.
J Mol Neurosci. 2010 May;41(1):114-20. doi: 10.1007/s12031-009-9300-x. Epub 2009 Oct 21.
NAP protects against cytochrome c release: inhibition of the initiation of apoptosis.
Zemlyak I, Sapolsky R, Gozes I.
Eur J Pharmacol. 2009 Sep 15;618(1-3):9-14. doi: 10.1016/j.ejphar.2009.07.013. Epub 2009 Jul 18.
Neuroprotective protein and carboxypeptidase E.
Koshimizu H, Senatorov V, Loh YP, Gozes I.
J Mol Neurosci. 2009 Sep;39(1-2):1-8. doi: 10.1007/s12031-008-9164-5. Epub 2009 Jan 23. Review.
NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42).
Gozes I, Divinski I, Piltzer I.
BMC Neurosci. 2008 Dec 10;9 Suppl 3:S3. doi: 10.1186/1471-2202-9-S3-S3.
The neuropeptide NAP provides neuroprotection against retinal ganglion cell damage after retinal ischemia and optic nerve crush.
Jehle T, Dimitriu C, Auer S, Knoth R, Vidal-Sanz M, Gozes I, Lagrèze WA.
Graefes Arch Clin Exp Ophthalmol. 2008 Sep;246(9):1255-63. doi: 10.1007/s00417-007-0746-7. Epub 2008 Apr 15. Erratum in: Graefes Arch Clin Exp Ophthalmol. 2008 Sep;246(9):1355.
ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance.
Mandel S, Spivak-Pohis I, Gozes I.
J Mol Neurosci. 2008 Jun;35(2):127-41. doi: 10.1007/s12031-007-9013-y. Epub 2008 Feb 20.
NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell.
Gozes I, Divinski I.
Curr Alzheimer Res. 2007 Dec;4(5):507-9.
Silencing of the ADNP-family member, ADNP2, results in changes in cellular viability under oxidative stress.
Kushnir M, Dresner E, Mandel S, Gozes I.
J Neurochem. 2008 Apr;105(2):537-45. doi: 10.1111/j.1471-4159.2007.05173.x. Epub 2007 Dec 19.
Vasoactive intestinal peptide (VIP) regulates activity-dependent neuroprotective protein (ADNP) expression in vivo.
Giladi E, Hill JM, Dresner E, Stack CM, Gozes I.
J Mol Neurosci. 2007;33(3):278-83. Epub 2007 Oct 2.
Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex.
Mandel S, Gozes I.
J Biol Chem. 2007 Nov 23;282(47):34448-56. Epub 2007 Sep 18.
NAP protects hippocampal neurons against multiple toxins.
Zemlyak I, Manley N, Sapolsky R, Gozes I.
Peptides. 2007 Oct;28(10):2004-8. Epub 2007 Aug 11.
Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry.
Hill JM, Hauser JM, Sheppard LM, Abebe D, Spivak-Pohis I, Kushnir M, Deitch I, Gozes I.
J Mol Neurosci. 2007;31(3):183-200.
Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.
Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, Gozes I.
J Pharmacol Exp Ther. 2007 Nov;323(2):438-49. Epub 2007 Aug 24.
Activity-dependent neuroprotective protein: from gene to drug candidate.
Gozes I.
Pharmacol Ther. 2007 May;114(2):146-54. Epub 2007 Feb 1. Review.
Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis.
Mandel S, Rechavi G, Gozes I.
Dev Biol. 2007 Mar 15;303(2):814-24. Epub 2006 Dec 1.
NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function.
Quintana FJ, Zaltzman R, Fernandez-Montesinos R, Herrera JL, Gozes I, Cohen IR, Pozo D.
Ann N Y Acad Sci. 2006 Jul;1070:500-6.
Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes.
Furman S, Steingart RA, Mandel S, Hauser JM, Brenneman DE, Gozes I.
Neuron Glia Biol. 2004 Aug;1(3):193-9.
Neurotrophic effects of the peptide NAP: a novel neuroprotective drug candidate.
Gozes I, Spivak-Pohis I.
Curr Alzheimer Res. 2006 Jul;3(3):197-9. Review.
NAP enhances neurodevelopment of newborn apolipoprotein E-deficient mice subjected to hypoxia.
Rotstein M, Bassan H, Kariv N, Speiser Z, Harel S, Gozes I.
J Pharmacol Exp Ther. 2006 Oct;319(1):332-9. Epub 2006 Jul 5. Erratum in: J Pharmacol Exp Ther. 2007 Jan;320(1):498.
Recombinant activity-dependent neuroprotective protein protects cells against oxidative stress.
Steingart RA, Gozes I.
Mol Cell Endocrinol. 2006 Jun 27;252(1-2):148-53. Epub 2006 May 15.
NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).
Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y, van Dyck CH, Thal L.
CNS Drug Rev. 2005 Winter;11(4):353-68. Review.
Brain deficits associated with fetal alcohol exposure may be protected, in part, by peptides derived from activity-dependent neurotrophic factor and activity-dependent neuroprotective protein.
Sari Y, Gozes I.
Brain Res Rev. 2006 Aug 30;52(1):107-18. Epub 2006 Feb 20. Review.
PolyADP-ribosylation is involved in neurotrophic activity.
Visochek L, Steingart RA, Vulih-Shultzman I, Klein R, Priel E, Gozes I, Cohen-Armon M.
J Neurosci. 2005 Aug 10;25(32):7420-8.
The influence of the peptide NAP on Mac-1-deficient mice following closed head injury.
Zaltzman R, Alexandrovich A, Trembovler V, Shohami E, Gozes I.
Peptides. 2005 Aug;26(8):1520-7. Epub 2005 Apr 15.
Neuropeptide receptor transcripts are expressed in the rat clitoris and oscillate during the estrus cycle in the rat vagina.
Dangoor D, Giladi E, Fridkin M, Gozes I.
Peptides. 2005 Dec;26(12):2579-84. Epub 2005 Jul 14.
The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury.
Gozes I, Zaltzman R, Hauser J, Brenneman DE, Shohami E, Hill JM.
Curr Alzheimer Res. 2005 Apr;2(2):149-53.
The peptides ADNF-9 and NAP increase survival and neurite outgrowth of rat retinal ganglion cells in vitro.
Lagrèze WA, Pielen A, Steingart R, Schlunck G, Hofmann HD, Gozes I, Kirsch M.
Invest Ophthalmol Vis Sci. 2005 Mar;46(3):933-8.
The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection.
Gozes I, Divinski I.
J Alzheimers Dis. 2004 Dec;6(6 Suppl):S37-41.
Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus.
Furman S, Hill JM, Vulih I, Zaltzman R, Hauser JM, Brenneman DE, Gozes I.
Neurosci Lett. 2005 Jan 3;373(1):73-8.
Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP.
Zusev M, Gozes I.
Regul Pept. 2004 Dec 15;123(1-3):33-41.
Brain injury-dependent expression of activity-dependent neuroprotective protein.
Zaltzman R, Alexandrovich A, Beni SM, Trembovler V, Shohami E, Gozes I.
J Mol Neurosci. 2004;24(2):181-7.
From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division.
Gozes I, Divinsky I, Pilzer I, Fridkin M, Brenneman DE, Spier AD.
J Mol Neurosci. 2003;20(3):315-22. Review.
Activity-dependent neuroprotective protein: a novel gene essential for brain formation.
Pinhasov A, Mandel S, Torchinsky A, Giladi E, Pittel Z, Goldsweig AM, Servoss SJ, Brenneman DE, Gozes I.
Brain Res Dev Brain Res. 2003 Aug 12;144(1):83-90.
Differential expression of embryonic and maternal activity-dependent neuroprotective protein during mouse development.
Poggi SH, Vink J, Goodwin K, Hill JM, Brenneman DE, Pinhasov A, Gozes I, Spong CY.
Am J Obstet Gynecol. 2002 Oct;187(4):973-6.
A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury: gene Atlas array analysis.
Romano J, Beni-Adani L, Nissenbaum OL, Brenneman DE, Shohami E, Gozes I.
J Mol Neurosci. 2002 Feb-Apr;18(1-2):37-45.
VIP-Related protection against lodoacetate toxicity in pheochromocytoma (PC12) cells: a model for ischemic/hypoxic injury.
Sigalov E, Fridkin M, Brenneman DE, Gozes I.
J Mol Neurosci. 2000 Dec;15(3):147-54.
A novel VIP responsive gene. Activity dependent neuroprotective protein.
Gozes I, Zamostiano R, Pinhasov A, Bassan M, Giladi E, Steingart RA, Brenneman DE.
Ann N Y Acad Sci. 2000;921:115-8.
A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice.
Beni-Adani L, Gozes I, Cohen Y, Assaf Y, Steingart RA, Brenneman DE, Eizenberg O, Trembolver V, Shohami E.
J Pharmacol Exp Ther. 2001 Jan;296(1):57-63.
A novel peptide prevents death in enriched neuronal cultures.
Zemlyak I, Furman S, Brenneman DE, Gozes I.
Regul Pept. 2000 Dec 22;96(1-2):39-43.
Cloning and characterization of the human activity-dependent neuroprotective protein.
Zamostiano R, Pinhasov A, Gelber E, Steingart RA, Seroussi E, Giladi E, Bassan M, Wollman Y, Eyre HJ, Mulley JC, Brenneman DE, Gozes I.
J Biol Chem. 2001 Jan 5;276(1):708-14.
Protective peptides derived from novel glial proteins.
Brenneman DE, Spong CY, Gozes I.
Biochem Soc Trans. 2000;28(4):452-5. Review. Erratum in: Biochem Soc Trans 2000 Dec;28(6):983.
A new concept in the pharmacology of neuroprotection.
Gozes I, Brenneman DE.
J Mol Neurosci. 2000 Feb-Apr;14(1-2):61-8. Review.
Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease.
Offen D, Sherki Y, Melamed E, Fridkin M, Brenneman DE, Gozes I.
Brain Res. 2000 Jan 31;854(1-2):257-62.
A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein.
Gozes I, Bassan M, Zamostiano R, Pinhasov A, Davidson A, Giladi E, Perl O, Glazner GW, Brenneman DE.
Ann N Y Acad Sci. 1999;897:125-35. Review.ADNP promotes neural differentiation by modulating Wnt/beta-catenin signaling.Sun X, Peng X, Cao Y, Zhou Y, Sun Y.Nat Commun. 2020 Jun 12;11(1):2984. doi: 10.1038/s41467-020-16799-0.PMID: 32533114
ADNP differentially interact with genes/proteins in correlation with aging: a novel marker for muscle aging.Kapitansky O, Gozes I.Geroscience. 2019 Jun;41(3):321-340. doi: 10.1007/s11357-019-00079-x. Epub 2019 Jul 1.PMID: 31264075
ADNP PUBLICATIONS
Below are links to medical and research publications regarding ADNP Syndrome / Helsmoortel - Van Der Aa Syndrome and activity dependent neuro-protective protein.
PUBLICATIONS WITH CONTRIBUTION INVOLVING ADNP KIDS RESEARCH FOUNDATION:
Sensory Reactivity Symptoms Are a Core Feature of ADNP Syndrome Irrespective of Autism Diagnosis
Siper PM, Layton C, Levy T, Lurie S, Benrey N, Zweifach J, Rowe M, Tang L, Guillory S, Halpern D, Giserman-Kiss I, Del Pilar Trelles M, Foss-Feig JH, De Rubeis S, Tavassoli T, Buxbaum JD, Kolevzon A.Genes (Basel). 2021 Feb 27;12(3):351. doi: 10.3390/genes12030351.PMID: 33673501
Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism
F. Kyle Satterstrom, Jack A. Kosmicki, Jiebiao Wang, ..., Kathryn Roeder, Mark J. Daly, Joseph D. Buxbaum
Cell 2020 Jan
Episignatures Stratifying Helsmoortel-Van Der Aa Syndrome Show Modest Correlation with Phenotype.
Breen MS, Garg P, Tang L, Mendonca D, Levy T, Barbosa M, Arnett AB, Kurtz-Nelson E, Agolini E, Battaglia A, Chiocchetti AG, Freitag CM, Garcia-Alcon A, Grammatico P, Hertz-Picciotto I, Ludena-Rodriguez Y, Moreno C, Novelli A, Parellada M, Pascolini G, Tassone F, Grice DE, Di Marino D, Bernier RA, Kolevzon A, Sharp AJ, Buxbaum JD, Siper PM, De Rubeis S.Am J Hum Genet. 2020 Sep 3;107(3):555-563. doi: 10.1016/j.ajhg.2020.07.003. Epub 2020 Aug 5.PMID: 32758449
The autism spectrum phenotype in ADNP syndrome.
Arnett AB, Rhoads CL, Hoekzema K, Turner TN, Gerdts J, Wallace AS, Bedrosian-Sermone S, Eichler EE, Bernier RA.
Autism Res. 2018 Sep;11(9):1300-1310. doi: 10.1002/aur.1980. Epub 2018 Aug 14.
Premature primary tooth eruption in cognitive/motor-delayed ADNP-mutated children.
Gozes I, Van Dijck A, Hacohen-Kleiman G, Grigg I, Karmon G, Giladi E, Eger M, Gabet Y, Pasmanik-Chor M, Cappuyns E, Elpeleg O, Kooy RF, Bedrosian-Sermone S.
Transl Psychiatry. 2017 Jul 4;7(7):e1166. doi: 10.1038/tp.2017.128.
www.mdpi.com/2073-4425/12/3/351/pdf
Clinical Presentation of a Complex Neurodevelopmental Disorder Caused by Mutations in ADNP.
Van Dijck A, Vulto-van Silfhout AT, Cappuyns E, van der Werf IM, Mancini GM, Tzschach A, Bernier R, Gozes I, Eichler EE, Romano C, Lindstrand A, Nordgren A; ADNP Consortium, Kvarnung M, Kleefstra T, de Vries BBA, Küry S, Rosenfeld JA, Meuwissen ME, Vandeweyer G, Kooy RF.
Biol Psychiatry. 2019 Feb 15;85(4):287-297. doi: 10.1016/j.biopsych.2018.02.1173. Epub 2018 Mar 15.
ADNP Consortium includes Bedrosian-Sermone S.
The Eight and a Half Year Journey of Undiagnosed AD: Gene Sequencing and Funding of Advanced Genetic Testing Has Led to Hope and New Beginnings.
Gozes I, Patterson MC, Van Dijck A, Kooy RF, Peeden JN, Eichenberger JA, Zawacki-Downing A, Bedrosian-Sermone S.
Front Endocrinol (Lausanne). 2017 May 19;8:107. doi: 10.3389/fendo.2017.00107. eCollection 2017.
The Compassionate Side of Neuroscience: Tony Sermone's Undiagnosed Genetic Journey--ADNPMutation.
Gozes I, Helsmoortel C, Vandeweyer G, Van der Aa N, Kooy F, Bedrosian-Sermone S.
J Mol Neurosci. 2015 Aug;56(4):751-757. doi: 10.1007/s12031-015-0586-6.
LIST OF ADDITONAL RELATED ADNP PUBLICATIONS:
Frank Kooy
Chromatin remodeler Activity-Dependent Neuroprotective Protein (ADNP) contributes to syndromic autism.
Claudio Peter D'Incal, Kirsten Esther Van Rossem, Kevin De Man, Anthony Konings, Anke Van Dijck, Ludovico Rizzuti, Alessandro Vitriolo, Giuseppe Testa, Illana Gozes, Wim Vanden Berghe,
2023 March 21, doi: 10.1186/s13148-023-01450-8
Single Cell ADNP Predictive of Human Muscle Disorders: Mouse Knockdown Results in Muscle Wasting.
Kapitansky O, Karmon G, Sragovich S, Hadar A, Shahoha M, Jaljuli I, Bikovski L, Giladi E, Palovics R, Iram T, Gozes I.Cells. 2020 Oct 19;9(10):2320. doi: 10.3390/cells9102320.PMID: 33086621
The ADNP Syndrome and CP201 (NAP) Potential and Hope.
Gozes I.Front Neurol. 2020 Nov 24;11:608444. doi: 10.3389/fneur.2020.608444. eCollection 2020.PMID: 33329371
Activity-dependent neuroprotective protein (ADNP)-end-binding protein (EB) interactions regulate microtubule dynamics toward protection against tauopathy.
Ivashko-Pachima Y, Gozes I.Prog Mol Biol Transl Sci. 2021;177:65-90. doi: 10.1016/bs.pmbts.2020.07.008. Epub 2020 Aug 14.PMID: 33453943
Sex-and Region-Dependent Expression of the Autism-Linked ADNP Correlates with Social- and Speech-Related Genes in the Canary Brain.
Hacohen-Kleiman G, Moaraf S, Kapitansky O, Gozes I.J Mol Neurosci. 2020 Nov;70(11):1671-1683. doi: 10.1007/s12031-020-01700-x. Epub 2020 Sep 14.PMID: 32926339
Developmental Predictors of Cognitive and Adaptive Outcomes in Genetic Subtypes of Autism Spectrum Disorder.
Arnett AB, Beighley JS, Kurtz-Nelson EC, Hoekzema K, Wang T, Bernier RA, Eichler EE.Autism Res. 2020 Oct;13(10):1659-1669. doi: 10.1002/aur.2385. Epub 2020 Sep 12.PMID: 32918531
ADNP Controls Gene Expression Through Local Chromatin Architecture by Association With BRG1 and CHD4.
Sun X, Yu W, Li L, Sun Y.Front Cell Dev Biol. 2020 Jul 1;8:553. doi: 10.3389/fcell.2020.00553. eCollection 2020.PMID: 32714933
Tauopathy in the young autistic brain: novel biomarker and therapeutic target.
Grigg I, Ivashko-Pachima Y, Hait TA, Korenková V, Touloumi O, Lagoudaki R, Van Dijck A, Marusic Z, Anicic M, Vukovic J, Kooy RF, Grigoriadis N, Gozes I.
ADNP promotes neural differentiation by modulating Wnt/beta-catenin signaling.Sun X, Peng X, Cao Y, Zhou Y, Sun Y., Nat Commun. 2020 Jun 12;11(1):2984. doi: 10.1038/s41467-020-16799-0.PMID: 32533114
Early behavioral and developmental interventions in ADNP-syndrome: A case report of SWI/SNF-related neurodevelopmental syndrome.
Shillington A, Pedapati E, Hopkin R, Suhrie K.Mol Genet Genomic Med. 2020 Jun;8(6):e1230. doi: 10.1002/mgg3.1230. Epub 2020 Apr 10.PMID: 32275126
Microbiota changes associated with ADNP deficiencies: rapid indicators for NAP (CP201) treatment of the ADNP syndrome and beyond.
Kapitansky O, Giladi E, Jaljuli I, Bereswill S, Heimesaat MM, Gozes I.J Neural Transm (Vienna). 2020 Feb;127(2):251-263. doi: 10.1007/s00702-020-02155-5. Epub 2020 Feb 18.PMID: 32072336
VIP/PACAP-Based Drug Development: The ADNP/NAP-Derived Mirror Peptides SKIP and D-SKIP Exhibit Distinctive in vivo and in silico Effects.
Sragovich S, Amram N, Yeheskel A, Gozes I.Front Cell Neurosci. 2020 Jan 14;13:589. doi: 10.3389/fncel.2019.00589. eCollection 2019.PMID: 31992971
The autism-mutated ADNP plays a key role in stress response.
Sragovich S, Ziv Y, Vaisvaser S, Shomron N, Hendler T, Gozes I.Transl Psychiatry. 2019 Sep 18;9(1):235. doi: 10.1038/s41398-019-0569-4.PMID: 31534115
The ChAHP Complex Counteracts Chromatin Looping at CTCF Sites that Emerged from SINE Expansions in Mouse.
Kaaij LJT, Mohn F, van der Weide RH, de Wit E, Bühler M.Cell. 2019 Sep 5;178(6):1437-1451.e14. doi: 10.1016/j.cell.2019.08.007.PMID: 31491387
NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies.
Ivashko-Pachima Y, Maor-Nof M, Gozes I.
PLoS One. 2019 Mar 13;14(3):e0213666. doi: 10.1371/journal.pone.0213666. eCollection 2019.
Cellular and animal models of skin alterations in the autism-related ADNP syndrome.
Mollinedo P, Kapitansky O, Gonzalez-Lamuño D, Zaslavsky A, Real P, Gozes I, Gandarillas A, Fernandez-Luna JL.
Sci Rep. 2019 Jan 24;9(1):736. doi: 10.1038/s41598-018-36859-2.
The autism/neuroprotection-linked ADNP/NAP regulate the excitatory glutamatergic synapse.
Sragovich S, Malishkevich A, Piontkewitz Y, Giladi E, Touloumi O, Lagoudaki R, Grigoriadis N, GozesI.
Transl Psychiatry. 2019 Jan 15;9(1):2. doi: 10.1038/s41398-018-0357-6.
Atypical Auditory Brainstem Response and Protein Expression Aberrations Related to ASD and Hearing Loss in the Adnp Haploinsufficient Mouse Brain.
Hacohen-Kleiman G, Yizhar-Barnea O, Touloumi O, Lagoudaki R, Avraham KB, Grigoriadis N, GozesI.
Neurochem Res. 2019 Jan 18. doi: 10.1007/s11064-019-02723-6. [Epub ahead of print]
ADNP Regulates Cognition: A Multitasking Protein.
Gozes I.
Front Neurosci. 2018 Nov 26;12:873. doi: 10.3389/fnins.2018.00873. eCollection 2018. No abstract available.
NAP Protects against Tau Hyperphosphorylation Through GSK3.
Ivashko-Pachima Y, Gozes I.
Curr Pharm Des. 2018;24(33):3868-3877. doi: 10.2174/1381612824666181112105954.
Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome.
Hacohen-Kleiman G, Sragovich S, Karmon G, Gao AYL, Grigg I, Pasmanik-Chor M, Le A, Korenková V, McKinney RA, Gozes I.
J Clin Invest. 2018 Nov 1;128(11):4956-4969. doi: 10.1172/JCI98199. Epub 2018 Sep 24.
Activity-dependent neuroprotective protein (ADNP) is an alcohol-responsive gene and negative regulator of alcohol consumption in female mice.
Ziv Y, Rahamim N, Lezmy N, Even-Chen O, Shaham O, Malishkevich A, Giladi E, Elkon R, Gozes I, Barak S.
Neuropsychopharmacology. 2019 Jan;44(2):415-424. doi: 10.1038/s41386-018-0132-7. Epub 2018 Jun 27.
Mutations in ADNP affect expression and subcellular localization of the protein.
Cappuyns E, Huyghebaert J, Vandeweyer G, Kooy RF.
Cell Cycle. 2018;17(9):1068-1075. doi: 10.1080/15384101.2018.1471313. Epub 2018 Jul 17.
The autism spectrum phenotype in ADNP syndrome.
Arnett AB, Rhoads CL, Hoekzema K, Turner TN, Gerdts J, Wallace AS, Bedrosian-Sermone S, Eichler EE, Bernier RA.
Autism Res. 2018 Sep;11(9):1300-1310. doi: 10.1002/aur.1980. Epub 2018 Aug 14.
Clinical Presentation of a Complex Neurodevelopmental Disorder Caused by Mutations in ADNP.
Van Dijck A, Vulto-van Silfhout AT, Cappuyns E, van der Werf IM, Mancini GM, Tzschach A, Bernier R, Gozes I, Eichler EE, Romano C, Lindstrand A, Nordgren A; ADNP Consortium, Kvarnung M, Kleefstra T, de Vries BBA, Küry S, Rosenfeld JA, Meuwissen ME, Vandeweyer G, Kooy RF.
Biol Psychiatry. 2019 Feb 15;85(4):287-297. doi: 10.1016/j.biopsych.2018.02.1173. Epub 2018 Mar 15.
A heterozygous microdeletion of 20q13.13 encompassing ADNP gene in a child with Helsmoortel-van der Aa syndrome.
Huynh MT, Boudry-Labis E, Massard A, Thuillier C, Delobel B, Duban-Bedu B, Vincent-Delorme C.
Eur J Hum Genet. 2018 Oct;26(10):1497-1501. doi: 10.1038/s41431-018-0165-8. Epub 2018 Jun 13.
Activity-dependent neuroprotective protein recruits HP1 and CHD4 to control lineage-specifying genes.
Ostapcuk V, Mohn F, Carl SH, Basters A, Hess D, Iesmantavicius V, Lampersberger L, Flemr M, Pandey A, Thomä NH, Betschinger J, Bühler M.
Nature. 2018 May;557(7707):739-743. doi: 10.1038/s41586-018-0153-8. Epub 2018 May 23.
Anti-inflammatory Effects of the Octapeptide NAP in Human Microbiota-Associated Mice Suffering from Subacute Ileitis.
Escher U, Giladi E, Dunay IR, Bereswill S, Gozes I, Heimesaat MM.
Eur J Microbiol Immunol (Bp). 2018 May 23;8(2):34-40. doi: 10.1556/1886.2018.00006. eCollection 2018 Jun 25.
ADNP, a Microtubule Interacting Protein, Provides Neuroprotection Through End Binding Proteins and Tau: An Amplifier Effect.
Gozes I, Ivashko-Pachima Y, Sayas CL.
Front Mol Neurosci. 2018 May 1;11:151. doi: 10.3389/fnmol.2018.00151. eCollection 2018. No abstract available.
Longitudinal ophthalmic findings in a child with Helsmoortel-Van der Aa Syndrome.
Gale MJ, Titus HE, Harman GA, Alabduljalil T, Dennis A, Wilson JL, Koeller DM, Finanger E, Blasco PA, Chiang PW, Karr DJ, Yang P.
Am J Ophthalmol Case Rep. 2018 Mar 13;10:244-248. doi: 10.1016/j.ajoc.2018.03.015. eCollection 2018 Jun.
Helsmoortel-Van der Aa Syndrome as emerging clinical diagnosis in intellectually disabled children with autistic traits and ocular involvement.
Pascolini G, Agolini E, Majore S, Novelli A, Grammatico P, Digilio MC.
Eur J Paediatr Neurol. 2018 May;22(3):552-557. doi: 10.1016/j.ejpn.2018.01.024. Epub 2018 Feb 3.
The octapetide NAP alleviates intestinal and extra-intestinal anti-inflammatory sequelae of acute experimental colitis.
Heimesaat MM, Giladi E, Kühl AA, Bereswill S, Gozes I.
Peptides. 2018 Mar;101:1-9. doi: 10.1016/j.peptides.2017.12.023. Epub 2017 Dec 27.
Specific protein biomarker patterns for Alzheimer's disease: improved diagnostics in progress.
Gozes I.
EPMA J. 2017 Sep 4;8(3):255-259. doi: 10.1007/s13167-017-0110-x. eCollection 2017 Sep. Review.
ADNP Plays a Key Role in Autophagy: From Autism to Schizophrenia and Alzheimer's Disease.
Sragovich S, Merenlender-Wagner A, Gozes I.
Bioessays. 2017 Nov;39(11). doi: 10.1002/bies.201700054. Epub 2017 Sep 21. Review.
Premature primary tooth eruption in cognitive/motor-delayed ADNP-mutated children.
Gozes I, Van Dijck A, Hacohen-Kleiman G, Grigg I, Karmon G, Giladi E, Eger M, Gabet Y, Pasmanik-Chor M, Cappuyns E, Elpeleg O, Kooy RF, Bedrosian-Sermone S.
Transl Psychiatry. 2017 Jul 4;7(7):e1166. doi: 10.1038/tp.2017.128.
The Eight and a Half Year Journey of Undiagnosed AD: Gene Sequencing and Funding of Advanced Genetic Testing Has Led to Hope and New Beginnings.
Gozes I, Patterson MC, Van Dijck A, Kooy RF, Peeden JN, Eichenberger JA, Zawacki-Downing A, Bedrosian-Sermone S.
Front Endocrinol (Lausanne). 2017 May 19;8:107. doi: 10.3389/fendo.2017.00107. eCollection 2017.
ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy.
Ivashko-Pachima Y, Sayas CL, Malishkevich A, Gozes I.
Mol Psychiatry. 2017 Sep;22(9):1335-1344. doi: 10.1038/mp.2016.255. Epub 2017 Jan 24.
Prenatal diagnosis of complex phenotype in a 13-week-old fetus with an interstitial multigene deletion 20q13.13.-q13.2 by chromosomal microarray.
Stipoljev F, Miric-Tesanic D, Hafner T, Barbalic M, Logara M, Lasan-Trcic R, Vicic A, Gjergja-Juraski R.
Eur J Med Genet. 2017 Nov;60(11):589-594. doi: 10.1016/j.ejmg.2017.08.010. Epub 2017 Aug 12.
Novel features of Helsmoortel-Van der Aa/ADNP syndrome in a boy with a known pathogenic mutation in the ADNP gene detected by exome sequencing.
Li C, Wang Y, Szybowska M.
Am J Med Genet A. 2017 May 5. doi: 10.1002/ajmg.a.38201. [Epub ahead of print] No abstract available.
Further evidence that a blepharophimosis syndrome phenotype is associated with a specific class of mutation in the ADNP gene.
Takenouchi T, Miwa T, Sakamoto Y, Sakaguchi Y, Uehara T, Takahashi T, Kosaki K.
Am J Med Genet A. 2017 Jun;173(6):1631-1634. doi: 10.1002/ajmg.a.38126.
Sexual divergence in activity-dependent neuroprotective protein impacting autism, schizophrenia, and Alzheimer's disease.
Gozes I.
J Neurosci Res. 2017 Jan 2;95(1-2):652-660. doi: 10.1002/jnr.23808. Review.
D-SAL and NAP: Two Peptides Sharing a SIP Domain.
Gozes I, Sragovich S, Schirer Y, Idan-Feldman A.
J Mol Neurosci. 2016 Jun;59(2):220-31. doi: 10.1007/s12031-015-0701-8.
Sexual divergence in microtubule function: the novel intranasal microtubule targeting SKIP normalizes axonal transport and enhances memory.
Amram N, Hacohen-Kleiman G, Sragovich S, Malishkevich A, Katz J, Touloumi O, Lagoudaki R, Grigoriadis NC, Giladi E, Yeheskel A, Pasmanik-Chor M, Jouroukhin Y, Gozes I.
Mol Psychiatry. 2016 Oct;21(10):1467-76. doi: 10.1038/mp.2015.208. Epub 2016 Jan 19.
Additional data on the clinical phenotype of Helsmoortel-Van der Aa syndrome associated with a novel truncating mutation in ADNP gene.
Krajewska-Walasek M, Jurkiewicz D, Piekutowska-Abramczuk D, Kucharczyk M, Chrzanowska KH, Jezela-Stanek A, Ciara E.
Am J Med Genet A. 2016 Jun;170(6):1647-50. doi: 10.1002/ajmg.a.37641.
Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers.
Malishkevich A, Marshall GA, Schultz AP, Sperling RA, Aharon-Peretz J, Gozes I.
J Alzheimers Dis. 2016;50(1):249-60. doi: 10.3233/JAD-150799.
ADNP: in search for molecular mechanisms and innovative therapeutic strategies for frontotemporal degeneration.
Gozes I, Ivashko-Pachima Y.
Front Aging Neurosci. 2015 Oct 29;7:205. doi: 10.3389/fnagi.2015.00205. eCollection 2015. Review.
Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model.
Vaisburd S, Shemer Z, Yeheskel A, Giladi E, Gozes I.
Sci Rep. 2015 Nov 10;5:16300. doi: 10.1038/srep16300.
Anti-Inflammatory Properties of NAP in Acute Toxoplasma Gondii-Induced Ileitis in Mice.
Heimesaat MM, Fischer A, Kühl AA, Göbel UB, Gozes I, Bereswill S.
Eur J Microbiol Immunol (Bp). 2015 Sep 18;5(3):210-20. doi: 10.1556/1886.2015.00025. eCollection 2015 Sep.
ADNP/ADNP2 expression in oligodendrocytes: implication for myelin-related neurodevelopment.
Malishkevich A, Leyk J, Goldbaum O, Richter-Landsberg C, Gozes I.
J Mol Neurosci. 2015 Oct;57(2):304-13. doi: 10.1007/s12031-015-0640-4.
The Compassionate Side of Neuroscience: Tony Sermone's Undiagnosed Genetic Journey--ADNPMutation.
Gozes I, Helsmoortel C, Vandeweyer G, Van der Aa N, Kooy F, Sermone SB.
J Mol Neurosci. 2015 Aug;56(4):751-757. doi: 10.1007/s12031-015-0586-6.
The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP.
Gozes I.
Biol Chem. 2016 Mar;397(3):177-84. doi: 10.1515/hsz-2015-0152. Review.
ADNP-Related Intellectual Disability and Autism Spectrum Disorder.
Van Dijck A, Helsmoortel C, Vandeweyer G, Kooy F.
In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews®[Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2016 Apr 7.
ADNP: A major autism mutated gene is differentially distributed (age and gender) in the songbird brain.
Hacohen Kleiman G, Barnea A, Gozes I.
Peptides. 2015 Oct;72:75-9. doi: 10.1016/j.peptides.2015.04.008. Epub 2015 Apr 17.
Activity-dependent neuroprotective protein (ADNP) exhibits striking sexual dichotomy impacting on autistic and Alzheimer's pathologies.
Malishkevich A, Amram N, Hacohen-Kleiman G, Magen I, Giladi E, Gozes I.
Transl Psychiatry. 2015 Feb 3;5:e501. doi: 10.1038/tp.2014.138.
Activity-dependent neuroprotective protein (ADNP): from autism to Alzheimer's disease.
Gozes I.
Springerplus. 2015 Jun 12;4(Suppl 1):L37. doi: 10.1186/2193-1801-4-S1-L37. eCollection 2015. No abstract available.
New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia.
Merenlender-Wagner A, Shemer Z, Touloumi O, Lagoudaki R, Giladi E, Andrieux A, Grigoriadis NC, Gozes I.
Autophagy. 2014;10(12):2324-32. doi: 10.4161/15548627.2014.984274.
Activity-dependent neuroprotective protein (ADNP): a case study for highly conserved chordata-specific genes shaping the brain and mutated in cancer.
Gozes I, Yeheskel A, Pasmanik-Chor M.
J Alzheimers Dis. 2015;45(1):57-73. doi: 10.3233/JAD-142490.
The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins.
Oz S, Kapitansky O, Ivashco-Pachima Y, Malishkevich A, Giladi E, Skalka N, Rosin-Arbesfeld R, Mittelman L, Segev O, Hirsch JA, Gozes I.
Mol Psychiatry. 2014 Oct;19(10):1115-24. doi: 10.1038/mp.2014.97. Epub 2014 Sep 2.
The transcriptional regulator ADNP links the BAF (SWI/SNF) complexes with autism.
Vandeweyer G, Helsmoortel C, Van Dijck A, Vulto-van Silfhout AT, Coe BP, Bernier R, Gerdts J, Rooms L, van den Ende J, Bakshi M, Wilson M, Nordgren A, Hendon LG, Abdulrahman OA, Romano C, de Vries BB, Kleefstra T, Eichler EE, Van der Aa N, Kooy RF.
Am J Med Genet C Semin Med Genet. 2014 Sep;166C(3):315-26. doi: 10.1002/ajmg.c.31413. Epub 2014 Aug 28.
Expansion of the clinical phenotype associated with mutations in activity-dependent neuroprotective protein.
Pescosolido MF, Schwede M, Johnson Harrison A, Schmidt M, Gamsiz ED, Chen WS, Donahue JP, Shur N, Jerskey BA, Phornphutkul C, Morrow EM.
J Med Genet. 2014 Sep;51(9):587-9. doi: 10.1136/jmedgenet-2014-102444. Epub 2014 Jul 23. No .
A SWI/SNF-related autism syndrome caused by de novo mutations in ADNP.
Helsmoortel C, Vulto-van Silfhout AT, Coe BP, Vandeweyer G, Rooms L, van den Ende J, Schuurs-Hoeijmakers JH, Marcelis CL, Willemsen MH, Vissers LE, Yntema HG, Bakshi M, Wilson M, Witherspoon KT, Malmgren H, Nordgren A, Annerén G, Fichera M, Bosco P, Romano C, de Vries BB, Kleefstra T, Kooy RF, Eichler EE, Van der Aa N.
Nat Genet. 2014 Apr;46(4):380-4. doi: 10.1038/ng.2899. Epub 2014 Feb 16.
Davunetide: Peptide therapeutic in neurological disorders.
Magen I, Gozes I.
Curr Med Chem. 2014;21(23):2591-8. Review.
Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide).
Gozes I, Iram T, Maryanovsky E, Arviv C, Rozenberg L, Schirer Y, Giladi E, Furman-Assaf S.
J Alzheimers Dis. 2014;40 Suppl 1:S23-36. doi: 10.3233/JAD-131664.
Novel marker for the onset of frontotemporal dementia: early increase in activity-dependent neuroprotective protein (ADNP) in the face of Tau mutation.
Schirer Y, Malishkevich A, Ophir Y, Lewis J, Giladi E, Gozes I.
PLoS One. 2014 Jan 29;9(1):e87383. doi: 10.1371/journal.pone.0087383. eCollection 2014.
NAP alpha-aminoisobutyric acid (IsoNAP).
Gozes I, Schirer Y, Idan-Feldman A, David M, Furman-Assaf S.
J Mol Neurosci. 2014 Jan;52(1):1-9. doi: 10.1007/s12031-013-0103-8.
Autophagy has a key role in the pathophysiology of schizophrenia.
Merenlender-Wagner A, Malishkevich A, Shemer Z, Udawela M, Gibbons A, Scarr E, Dean B, Levine J, Agam G, Gozes I.
Mol Psychiatry. 2015 Feb;20(1):126-32. doi: 10.1038/mp.2013.174. Epub 2013 Dec 24.
Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP).
Magen I, Gozes I.
Neuropeptides. 2013 Dec;47(6):489-95. doi: 10.1016/j.npep.2013.10.011. Epub 2013 Oct 24. Review.
The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities.
Oz S, Ivashko-Pachima Y, Gozes I.
PLoS One. 2012;7(12):e51458. doi: 10.1371/journal.pone.0051458. Epub 2012 Dec 14.
Neuropeptide GPCRs in neuroendocrinology: the case of activity-dependent neuroprotective protein (ADNP).
Gozes I.
Front Endocrinol (Lausanne). 2012 Nov 16;3:134. doi: 10.3389/fendo.2012.00134. eCollection 2012. No abstract available.
Novel evolutionary-conserved role for the activity-dependent neuroprotective protein (ADNP) family that is important for erythropoiesis.
Dresner E, Malishkevich A, Arviv C, Leibman Barak S, Alon S, Ofir R, Gothilf Y, Gozes I.
J Biol Chem. 2012 Nov 23;287(48):40173-85. doi: 10.1074/jbc.M112.387027. Epub 2012 Oct 15.
D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy.
Jouroukhin Y, Ostritsky R, Gozes I.
J Mol Neurosci. 2012 Nov;48(3):597-602. Review.
Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).
Gozes I.
Curr Pharm Des. 2011;17(31):3413-7. Review.
Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.
Shiryaev N, Pikman R, Giladi E, Gozes I.
Curr Pharm Des. 2011;17(25):2603-12. Review.
NAP (davunetide) provides functional and structural neuroprotection.
Gozes I.
Curr Pharm Des. 2011;17(10):1040-4. Review.
Ameliorative effect of NAP on laser-induced retinal damage.
Belokopytov M, Shulman S, Dubinsky G, Gozes I, Belkin M, Rosner M.
Acta Ophthalmol. 2011 Mar;89(2):e126-31. doi: 10.1111/j.1755-3768.2010.02041.x. Epub 2011 Feb 2.
Neuroprotective effects of NAP against excitotoxic brain damage in the newborn mice: implications for cerebral palsy.
Sokolowska P, Passemard S, Mok A, Schwendimann L, Gozes I, Gressens P.
Neuroscience. 2011 Jan 26;173:156-68. doi: 10.1016/j.neuroscience.2010.10.074. Epub 2010 Nov 10.
Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate.
Gozes I.
Peptides. 2011 Feb;32(2):428-31. doi: 10.1016/j.peptides.2010.10.030. Epub 2010 Nov 2. Review.
Tau pathology and future therapeutics.
Gozes I.
Curr Alzheimer Res. 2010 Dec;7(8):685-96. Review.
Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia.
Dresner E, Agam G, Gozes I.
Eur Neuropsychopharmacol. 2011 May;21(5):355-61. doi: 10.1016/j.euroneuro.2010.06.004. Epub 2010 Jul 3.
NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia.
Merenlender-Wagner A, Pikman R, Giladi E, Andrieux A, Gozes I.
Peptides. 2010 Jul;31(7):1368-73. doi: 10.1016/j.peptides.2010.04.011. Epub 2010 Apr 22.
Addressing Alzheimer's disease tangles: from NAP to AL-108.
Gozes I, Stewart A, Morimoto B, Fox A, Sutherland K, Schmeche D.
Curr Alzheimer Res. 2009 Oct;6(5):455-60. Review.
Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease.
Fernandez-Montesinos R, Torres M, Baglietto-Vargas D, Gutierrez A, Gozes I, Vitorica J, Pozo D.
J Mol Neurosci. 2010 May;41(1):114-20. doi: 10.1007/s12031-009-9300-x. Epub 2009 Oct 21.
NAP protects against cytochrome c release: inhibition of the initiation of apoptosis.
Zemlyak I, Sapolsky R, Gozes I.
Eur J Pharmacol. 2009 Sep 15;618(1-3):9-14. doi: 10.1016/j.ejphar.2009.07.013. Epub 2009 Jul 18.
Neuroprotective protein and carboxypeptidase E.
Koshimizu H, Senatorov V, Loh YP, Gozes I.
J Mol Neurosci. 2009 Sep;39(1-2):1-8. doi: 10.1007/s12031-008-9164-5. Epub 2009 Jan 23. Review.
NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42).
Gozes I, Divinski I, Piltzer I.
BMC Neurosci. 2008 Dec 10;9 Suppl 3:S3. doi: 10.1186/1471-2202-9-S3-S3.
The neuropeptide NAP provides neuroprotection against retinal ganglion cell damage after retinal ischemia and optic nerve crush.
Jehle T, Dimitriu C, Auer S, Knoth R, Vidal-Sanz M, Gozes I, Lagrèze WA.
Graefes Arch Clin Exp Ophthalmol. 2008 Sep;246(9):1255-63. doi: 10.1007/s00417-007-0746-7. Epub 2008 Apr 15. Erratum in: Graefes Arch Clin Exp Ophthalmol. 2008 Sep;246(9):1355.
ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance.
Mandel S, Spivak-Pohis I, Gozes I.
J Mol Neurosci. 2008 Jun;35(2):127-41. doi: 10.1007/s12031-007-9013-y. Epub 2008 Feb 20.
NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell.
Gozes I, Divinski I.
Curr Alzheimer Res. 2007 Dec;4(5):507-9.
Silencing of the ADNP-family member, ADNP2, results in changes in cellular viability under oxidative stress.
Kushnir M, Dresner E, Mandel S, Gozes I.
J Neurochem. 2008 Apr;105(2):537-45. doi: 10.1111/j.1471-4159.2007.05173.x. Epub 2007 Dec 19.
Vasoactive intestinal peptide (VIP) regulates activity-dependent neuroprotective protein (ADNP) expression in vivo.
Giladi E, Hill JM, Dresner E, Stack CM, Gozes I.
J Mol Neurosci. 2007;33(3):278-83. Epub 2007 Oct 2.
Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex.
Mandel S, Gozes I.
J Biol Chem. 2007 Nov 23;282(47):34448-56. Epub 2007 Sep 18.
NAP protects hippocampal neurons against multiple toxins.
Zemlyak I, Manley N, Sapolsky R, Gozes I.
Peptides. 2007 Oct;28(10):2004-8. Epub 2007 Aug 11.
Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry.
Hill JM, Hauser JM, Sheppard LM, Abebe D, Spivak-Pohis I, Kushnir M, Deitch I, Gozes I.
J Mol Neurosci. 2007;31(3):183-200.
Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.
Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, Gozes I.
J Pharmacol Exp Ther. 2007 Nov;323(2):438-49. Epub 2007 Aug 24.
Activity-dependent neuroprotective protein: from gene to drug candidate.
Gozes I.
Pharmacol Ther. 2007 May;114(2):146-54. Epub 2007 Feb 1. Review.
Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis.
Mandel S, Rechavi G, Gozes I.
Dev Biol. 2007 Mar 15;303(2):814-24. Epub 2006 Dec 1.
NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function.
Quintana FJ, Zaltzman R, Fernandez-Montesinos R, Herrera JL, Gozes I, Cohen IR, Pozo D.
Ann N Y Acad Sci. 2006 Jul;1070:500-6.
Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes.
Furman S, Steingart RA, Mandel S, Hauser JM, Brenneman DE, Gozes I.
Neuron Glia Biol. 2004 Aug;1(3):193-9.
Neurotrophic effects of the peptide NAP: a novel neuroprotective drug candidate.
Gozes I, Spivak-Pohis I.
Curr Alzheimer Res. 2006 Jul;3(3):197-9. Review.
NAP enhances neurodevelopment of newborn apolipoprotein E-deficient mice subjected to hypoxia.
Rotstein M, Bassan H, Kariv N, Speiser Z, Harel S, Gozes I.
J Pharmacol Exp Ther. 2006 Oct;319(1):332-9. Epub 2006 Jul 5. Erratum in: J Pharmacol Exp Ther. 2007 Jan;320(1):498.
Recombinant activity-dependent neuroprotective protein protects cells against oxidative stress.
Steingart RA, Gozes I.
Mol Cell Endocrinol. 2006 Jun 27;252(1-2):148-53. Epub 2006 May 15.
NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).
Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y, van Dyck CH, Thal L.
CNS Drug Rev. 2005 Winter;11(4):353-68. Review.
Brain deficits associated with fetal alcohol exposure may be protected, in part, by peptides derived from activity-dependent neurotrophic factor and activity-dependent neuroprotective protein.
Sari Y, Gozes I.
Brain Res Rev. 2006 Aug 30;52(1):107-18. Epub 2006 Feb 20. Review.
PolyADP-ribosylation is involved in neurotrophic activity.
Visochek L, Steingart RA, Vulih-Shultzman I, Klein R, Priel E, Gozes I, Cohen-Armon M.
J Neurosci. 2005 Aug 10;25(32):7420-8.
The influence of the peptide NAP on Mac-1-deficient mice following closed head injury.
Zaltzman R, Alexandrovich A, Trembovler V, Shohami E, Gozes I.
Peptides. 2005 Aug;26(8):1520-7. Epub 2005 Apr 15.
Neuropeptide receptor transcripts are expressed in the rat clitoris and oscillate during the estrus cycle in the rat vagina.
Dangoor D, Giladi E, Fridkin M, Gozes I.
Peptides. 2005 Dec;26(12):2579-84. Epub 2005 Jul 14.
The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury.
Gozes I, Zaltzman R, Hauser J, Brenneman DE, Shohami E, Hill JM.
Curr Alzheimer Res. 2005 Apr;2(2):149-53.
The peptides ADNF-9 and NAP increase survival and neurite outgrowth of rat retinal ganglion cells in vitro.
Lagrèze WA, Pielen A, Steingart R, Schlunck G, Hofmann HD, Gozes I, Kirsch M.
Invest Ophthalmol Vis Sci. 2005 Mar;46(3):933-8.
The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection.
Gozes I, Divinski I.
J Alzheimers Dis. 2004 Dec;6(6 Suppl):S37-41.
Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus.
Furman S, Hill JM, Vulih I, Zaltzman R, Hauser JM, Brenneman DE, Gozes I.
Neurosci Lett. 2005 Jan 3;373(1):73-8.
Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP.
Zusev M, Gozes I.
Regul Pept. 2004 Dec 15;123(1-3):33-41.
Brain injury-dependent expression of activity-dependent neuroprotective protein.
Zaltzman R, Alexandrovich A, Beni SM, Trembovler V, Shohami E, Gozes I.
J Mol Neurosci. 2004;24(2):181-7.
From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division.
Gozes I, Divinsky I, Pilzer I, Fridkin M, Brenneman DE, Spier AD.
J Mol Neurosci. 2003;20(3):315-22. Review.
Activity-dependent neuroprotective protein: a novel gene essential for brain formation.
Pinhasov A, Mandel S, Torchinsky A, Giladi E, Pittel Z, Goldsweig AM, Servoss SJ, Brenneman DE, Gozes I.
Brain Res Dev Brain Res. 2003 Aug 12;144(1):83-90.
Differential expression of embryonic and maternal activity-dependent neuroprotective protein during mouse development.
Poggi SH, Vink J, Goodwin K, Hill JM, Brenneman DE, Pinhasov A, Gozes I, Spong CY.
Am J Obstet Gynecol. 2002 Oct;187(4):973-6.
A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury: gene Atlas array analysis.
Romano J, Beni-Adani L, Nissenbaum OL, Brenneman DE, Shohami E, Gozes I.
J Mol Neurosci. 2002 Feb-Apr;18(1-2):37-45.
VIP-Related protection against lodoacetate toxicity in pheochromocytoma (PC12) cells: a model for ischemic/hypoxic injury.
Sigalov E, Fridkin M, Brenneman DE, Gozes I.
J Mol Neurosci. 2000 Dec;15(3):147-54.
A novel VIP responsive gene. Activity dependent neuroprotective protein.
Gozes I, Zamostiano R, Pinhasov A, Bassan M, Giladi E, Steingart RA, Brenneman DE.
Ann N Y Acad Sci. 2000;921:115-8.
A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice.
Beni-Adani L, Gozes I, Cohen Y, Assaf Y, Steingart RA, Brenneman DE, Eizenberg O, Trembolver V, Shohami E.
J Pharmacol Exp Ther. 2001 Jan;296(1):57-63.
A novel peptide prevents death in enriched neuronal cultures.
Zemlyak I, Furman S, Brenneman DE, Gozes I.
Regul Pept. 2000 Dec 22;96(1-2):39-43.
Cloning and characterization of the human activity-dependent neuroprotective protein.
Zamostiano R, Pinhasov A, Gelber E, Steingart RA, Seroussi E, Giladi E, Bassan M, Wollman Y, Eyre HJ, Mulley JC, Brenneman DE, Gozes I.
J Biol Chem. 2001 Jan 5;276(1):708-14.
Protective peptides derived from novel glial proteins.
Brenneman DE, Spong CY, Gozes I.
Biochem Soc Trans. 2000;28(4):452-5. Review. Erratum in: Biochem Soc Trans 2000 Dec;28(6):983.
A new concept in the pharmacology of neuroprotection.
Gozes I, Brenneman DE.
J Mol Neurosci. 2000 Feb-Apr;14(1-2):61-8. Review.
Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease.
Offen D, Sherki Y, Melamed E, Fridkin M, Brenneman DE, Gozes I.
Brain Res. 2000 Jan 31;854(1-2):257-62.
A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein.
Gozes I, Bassan M, Zamostiano R, Pinhasov A, Davidson A, Giladi E, Perl O, Glazner GW, Brenneman DE.
Ann N Y Acad Sci. 1999;897:125-35. Review.ADNP promotes neural differentiation by modulating Wnt/beta-catenin signaling.Sun X, Peng X, Cao Y, Zhou Y, Sun Y.Nat Commun. 2020 Jun 12;11(1):2984. doi: 10.1038/s41467-020-16799-0.PMID: 32533114
ADNP differentially interact with genes/proteins in correlation with aging: a novel marker for muscle aging.Kapitansky O, Gozes I.Geroscience. 2019 Jun;41(3):321-340. doi: 10.1007/s11357-019-00079-x. Epub 2019 Jul 1.PMID: 31264075
